Axsome therapeutics' general counsel sells $2.28 million in stock

Axsome Therapeutics' General Counsel Hunter R. Murdock sold 22,500 shares for $2.28 million while exercising options for the same amount at $672,975, under a pre-approved 10b5-1 trading plan. This occurred as the company faces an FDA Refusal to File letter for its AXS-14 fibromyalgia treatment due to trial design inadequacies, prompting plans for a new trial in Q4 2025; analysts remain positive, focusing on Auvelity and Symbravo, with price targets ranging from $148 to $183.

Analysis

Axsome Therapeutics (NASDAQ:AXSM) recently saw its General Counsel, Hunter R. Murdock, sell 22,500 shares for approximately $2.28 million between June 16-18, 2025, at weighted average prices of $100.26 to $102.42, while simultaneously exercising options for the same share count at $29.91 each; these transactions were conducted under a pre-arranged 10b5-1 plan. This activity coincides with the stock trading near its InvestingPro Fair Value, having risen over 21% year-to-date, and the company maintaining strong gross profit margins of 91.5%. However, Axsome encountered a regulatory setback as the FDA issued a Refusal to File (RTF) letter for its AXS-14 New Drug Application for fibromyalgia, citing inadequacy in one trial's 8-week primary endpoint and flexible-dose design, though not the trial results themselves, as both trials met primary endpoints. Axsome plans a new trial with a 12-week endpoint and fixed-dose paradigm, expected to commence in Q4 2025. Despite this delay, analysts from Piper Sandler (Overweight, $148 PT), H.C. Wainwright (Buy, $180 PT), and Oppenheimer (Outperform, $183 PT, down from $185) remain positive, with Oppenheimer suggesting AXS-14 was not heavily factored into current valuations, and the company is expected to focus on Auvelity sales and the upcoming Symbravo launch.

Key Decisions for Investors

• Investors should closely monitor the initiation and progress of the new AXS-14 trial planned for Q4 2025, while recognizing that near-term performance will likely be driven by sales of Auvelity and the upcoming Symbravo launch.
• The General Counsel's stock sale, executed under a 10b5-1 plan concurrent with option exercises, should be interpreted as a likely pre-planned liquidity event or tax-related transaction rather than a definitive bearish signal on the company's immediate prospects.
• Evaluate Axsome's current valuation considering its robust 91.5% gross profit margin and sustained analyst optimism, weighing the impact of the AXS-14 development delay against the commercial potential of its marketed and other late-stage pipeline assets.